At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 540 enrolled
Drug / intervention
mRNA-1283 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2
In Brief
A Phase 2 clinical trial evaluating mRNA-1283, mRNA-1283.211, and 2 other interventions for SARS-CoV-2. Completed, enrolled 540 participants across 17 sites.
Detailed Summary
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates. The main goal of Part B of this study is to assess the safety, reactogenicity, and immunogenicity of the mRNA-1283.529 booster vaccine candidate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartDec 2021
Primary CompletionMar 2023
TodayJul 2026
First PostedNov 30, 2021
Enrollment StartDec 6, 2021
Primary CompletionMar 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.6 years ago
Interventions
mRNA-1283biological
Sterile liquid for injection
mRNA-1283.211biological
Sterile liquid for injection
mRNA-1273biological
Sterile liquid for injection
mRNA-1283.529biological
Sterile liquid for injection